Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single ascending dose study of OPC-184337 in healthy adult males
jRCT2071240031Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing OPC-184337 with Placebo (2 arms). Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started Oct 2024; status: recruiting.
02
Drugs
OPC-184337
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on jRCT2071240031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240031.